Suzhou Zelgen Biopharmaceuticals Co., Ltd.

苏州泽璟生物制药股份有限公司

Develops and commercializes innovative small-molecule and biologic therapies in China, focusing on oncology, autoimmune diseases, and hemostasis/hematology, with four commercialized drugs including Donafenib, a JAK inhibitor, recombinant human thrombin, and recombinant human thyrotropin.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Overlapping customers and suppliers
• Distribution model
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Inventory level and ageing
• Sanctioned countries and export controls